ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for high-throughput safety and efficacy screenings, in pharmaceutical, environmental, chemical, cosmetic or nutritional industries. With clients from 12 different countries worldwide, spanning from biotech up to pharma leaders/large academic centers, and a highly-qualified team, we guarantee a unique "zebrafish experience", as a one-way route of INNOVATION.
The company is currently preparing a Series A fundraising round to finance ZePharma, the drug discovery branch of ZeClinics. ZePharma has significantly shortened the time took to discover new therapeutic molecules, by utilizing ZeCardio, a zebrafish-based innovative high-throughput screening platform, developed by ZeClinics under the most prestigious grant program from the European Commission, SME Instrument Phase 2. The company is currently developing those molecules in CRISPR-edited pre-clinical models for unmet cardiovascular needs. It is divided into three business units, each with its own research goals, but all commonly started in zebrafish and by applying high throughput screening and “humanized” disease models generated with CRISPR genome editing technology: CardioProtection; Cardiomyopathies; CardioRegeneration;
The ticket of the investment seeked is of €5.000.000 to cover the upcoming pre-clinical and phase 1 clinical studies, with expected Return of the Investment in 4 years.